On March 16, 2026, Apimeds Pharmaceuticals US, Inc. (CIK: 0001894525) filed an 8-K report detailing the approval of a reverse stock split by its shareholders. The decision, made on December 1, 2025, allows the company to consolidate its outstanding shares at a ratio of 1-for-10. This move is aimed at increasing the per-share price of its common stock, which is expected to enhance its appeal to institutional investors and improve liquidity. The reverse stock split will take effect on March 26, 2026, with the company’s common stock trading under the symbol 'APUS' on the NYSE American LLC. The new CUSIP number for the common stock will be 03771D201. The company has indicated that this strategic decision is part of its broader plan to strengthen its market position and attract more investment. The reverse stock split is anticipated to have a positive impact on the stock price, although the exact effects will depend on market conditions and investor sentiment following the split.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.